Clinical Trial Update: Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation [Phase 3]

View source ↗

Summary

This entry reports a Phase 3 clinical trial evaluating sitagliptin to prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 3 | Status: COMPLETED